10-Q: RetinalGenix Reports Q2 Loss, Faces Going Concern Doubt

RetinalGenix Technologies Inc. reported a net loss of $1.24 million for the first half of 2025, with minimal cash and substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $1,236,677 for the six months ended June 30, 2025, an improvement from $2,809,509 in the same period of 2024.
• Cash balance stood at a critically low $839 as of June 30, 2025, down from $6,060 at December 31, 2024.
• Total liabilities increased to $1,989,553 at June 30, 2025, from $1,477,556 at December 31, 2024.
• Accumulated deficit reached $16,666,699 as of June 30, 2025.
• The company has not generated any revenue since its inception.
• Research and development expenses significantly decreased by 84% to $27,644 for the six months ended June 30, 2025, primarily due to a lack of funds.
• General and administrative expenses increased by 4% to $724,932 for the six months ended June 30, 2025.
• Management has concluded that disclosure controls and procedures were ineffective as of June 30, 2025, due to a material weakness in internal control over financial reporting related to a lack of segregation of duties.
• The company requires approximately $6,000,000 in additional operating capital to complete product development, seek FDA clearance for RetinalGenixTM, expand DNA/GPS technology, and build infrastructure.
• A pre-funded warrant for 28,014,540 shares cannot be exercised before February 1, 2030, or the third anniversary of a Nasdaq/NYSE American uplisting.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues, explicitly stating 'substantial doubt about our ability to continue as a going concern' with only $839 in cash. While the net loss improved, this was partly due to a significant reduction in R&D spending caused by a lack of funds, which is a negative operational indicator. The identified material weakness in internal controls further exacerbates concerns. The need for a substantial capital raise is critical and uncertain.

Positives

• Net loss for the six months ended June 30, 2025, improved to $1,236,677 from $2,809,509 in the prior year period.
• Net loss per share improved to $(0.07) from $(0.16) for the six months ended June 30, 2025.
• Progress continues on product development, including RetinalCamTM and Retinal Imaging Screening Device, and the Pearl IRB study for wet macular degeneration.
• The company is planning clinical studies for RTG-2023 (dry AMD) and RTG-2024 (Alzheimer's syndrome dementia).
• The Delaware Court of Chancery voided and cancelled 3,000,000 shares of Series F preferred stock issued to Halo and Gerrans, resolving a long-standing equity dispute.

Negatives

• Cash balance is critically low at $839 as of June 30, 2025, expected to fund operations for only a few days.
• Total liabilities increased to $1,989,553, with a significant portion ($900K+) owed to related parties.
• Accumulated deficit grew to $16,666,699.
• Research and development expenses decreased significantly (84%) due to a lack of funds, indicating a slowdown in core development activities.
• No revenue has been generated since inception.
• The company does not have adequate resources to fund operations beyond August 2026 without additional capital.
• Management concluded that disclosure controls and procedures were ineffective due to a material weakness in internal control over financial reporting (lack of segregation of duties).

Risks

• Substantial doubt about the company's ability to continue as a going concern due to minimal cash, significant liabilities, and expected continued operating losses and negative cash flows.
• Inability to raise additional funding on favorable terms or at all, which could force delays, reductions, or termination of product development and commercialization efforts.
• Uncertainty of future profitability, as the company has generated no revenue from commercial sales to date and products are still under development.
• Failure to maintain effective internal control over financial reporting could lead to inaccurate financial reports, regulatory sanctions, or damage to investor confidence.
• Dependence on related parties (Sanovas and others) for a significant portion of financing and operating expenses.
• Uncertainty regarding the duration and costs of future clinical trials and product development, and whether marketing clearance will be obtained.

Future Outlook

The company anticipates expanding its Pearl IRB study to multi-state physicians in September 2025, with initial analysis expected by the first quarter of 2026 to plan for clinical trials. It is also planning pharmaceutical clinical studies for RTG-2023 (dry AMD) and RTG-2024 (Alzheimer's syndrome dementia). The company expects operating losses and negative cash flows for at least the next several years and will need to raise approximately $6 million in additional capital to achieve its strategic goals, including completing product development and seeking FDA clearance for RetinalGenixTM.

Management Comments

• We anticipate an expansion of the IRB to multistate physicians in September 2025.
• We anticipate the initial analysis by the first quarter 2026, which will allow us to plan for our clinical trials.
• We expect that operating losses and negative cash flows from operations will occur for at least the next several years, and the Company will need to access additional funds to achieve its strategic goals.
• We are in discussions with investment bankers and individual investors with respect to raising additional capital for the Company and potentially up-listing to Nasdaq exchange.
• As of the date of this report, the Company does not have adequate resources to fund its operations through August 2026 without considering any potential future milestone payments that it may receive under any new collaborations that it may enter into in the future or any future capital raising transactions.
• Our management has concluded that our internal controls over financial reporting were, and continue to be, ineffective, and as of June 30, 2025 as a result of a material weakness in our internal controls.

Industry Context

The company operates in the highly competitive and capital-intensive ophthalmic and neurological medical device and pharmaceutical development sectors. Its focus on in-home monitoring, portable imaging, and genetic mapping for conditions like diabetic retinopathy, macular degeneration, and Alzheimer's aligns with trends towards personalized medicine and remote healthcare. However, its early stage of development, lack of revenue, and significant capital needs place it far behind established industry players and even many emerging biotechs that have secured substantial funding and advanced clinical pipelines.

Comparison to Industry Standards

• The company's lack of revenue and significant accumulated deficit are typical for early-stage biotech and medical device companies focused on R&D.
• The need for $6 million in additional capital for product design, testing, and FDA submission is a common requirement in the medical device industry, but the company's current cash position of $839 is extremely low compared to industry peers at similar development stages, which typically maintain cash reserves sufficient for at least 12-18 months of operations.
• The material weakness in internal controls due to lack of segregation of duties is a significant governance issue that would be a red flag compared to established public company standards.
• The reliance on related party financing is common for very early-stage ventures but becomes a concern for public companies seeking broader investor confidence.

Corporate Governance

Legal Proceedings

• The company received a claim against it relating to a former indirect vendor, which it believes is without merit and intends to vigorously defend. The company does not believe it would have a material impact on its financial condition.

Related Party Transactions

• Sanovas Ophthalmology, a majority-owned subsidiary of Sanovas Inc., formed the company and sublicensed technology to it.
• Jerry Katzman, the company's CEO, is also CEO of Sanovas and a director of Sanovas Ophthalmology.
• Sanovas pays a significant portion of the company's operating expenses and allocates costs for services.
• Balance due to Sanovas increased to $352,177 at June 30, 2025, from $15,709 at December 31, 2024.
• Advances from an officer, a shareholder, and other related parties totaled $547,148 at June 30, 2025, up from $467,793 at December 31, 2024.
• Shareholders notes payable of $49,000 remained outstanding, with an informal extension of maturity to December 31, 2026.
• The company issued 296,000 shares of common stock to offset $666,000 due to Sanovas in December 2024.
• The company entered into a sublicense agreement with Sanovas Ophthalmology for exclusive worldwide license to certain intellectual property.

Stakeholder Impact

• Shareholders face significant risk due to the going concern doubt, potential for substantial dilution from future capital raises, and uncertainty of product commercialization. The voiding of Series F preferred stock is positive for existing common shareholders by removing potential dilution/governance issues.
• Employees/Consultants: The company has no full-time employees and relies on Sanovas personnel and consultants, indicating job insecurity and dependence on related party support.
• Creditors (especially related parties) face high risk of non-repayment given the company's minimal cash and going concern issues.
• Customers/Patients: Future patients could benefit from the development of ophthalmic and neurological diagnostic/treatment technologies, but commercialization is highly uncertain and distant.

Next Steps

• Expand the Pearl IRB study to multi-state physicians (anticipated September 2025).
• Conduct initial analysis from the Pearl IRB study (anticipated Q1 2026) to plan for clinical trials.
• Move forward with contracted clinical resource organization to conduct pharmaceutical clinical studies for RTG-2023 (dry AMD) and RTG-2024 (Alzheimer's syndrome dementia).
• Raise approximately $6,000,000 in additional capital.
• Complete product design and testing for RetinalGenixTM and RetinalCamTM.
• Submit RetinalGenixTM for FDA clearance.
• Complete development and expansion of software tools for DNA/GPS genetic mapping technology.
• Build infrastructure for sustained growth.
• Implement remediation measures for the material weakness in internal control over financial reporting (expected in H2 2025, as resources permit).
• Potentially up-list to Nasdaq exchange.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt about our ability to continue as a going concern' with only $839 in cash. While the net loss decreased, this was largely due to a drastic 84% cut in R&D spending, indicating a forced slowdown in core development activities rather than operational efficiency. Liabilities are increasing, and the company is heavily reliant on related party financing. Furthermore, management has identified a material weakness in internal controls, which is a significant governance red flag. The need for a substantial $6 million capital raise is critical, yet uncertain, and any successful raise would likely result in significant dilution. Given the precarious financial position, operational slowdown, and governance issues, the stock presents a high risk of capital loss.

Keywords

ophthalmic technology, retinal imaging, diabetic retinopathy, maculopathy, Alzheimer's treatment, dry AMD treatment, medical devices, biotechnology, SEC filing, 10-Q, going concern, capital raise, clinical trials, DNA/GPS